NNOX$2.85
Chart
Performance
Key Stats
AI NNOX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralNano-X Imaging Ltd. exhibits mixed signals. While its innovative medical imaging technology addresses a growing market, significant losses, negative free cash flow, and a highly speculative valuation present considerable risks. The recent price performance has been poor, and technical indicators are mixed, leaning towards bearish in the short to medium term.
Thematic
Nano-X Imaging operates in the healthcare technology and medical imaging sectors, which are driven by aging populations, increasing demand for diagnostics, and advancements in AI for medical applications. The company's digital X-ray source technology is innovative, but its market penetration and adoption are still in early stages, creating both opportunity and uncertainty.
Fundamental
Nano-X Imaging's fundamentals are characterized by significant operating losses, negative profitability, and substantial negative free cash flow. While its cash position is adequate for the near term, its path to profitability is uncertain, and its valuation metrics are highly speculative.
Technical
The stock's recent performance has been highly negative, with significant price declines across multiple periods. Technical indicators suggest a bearish trend in the short to medium term, with some potential for short-term bounces, but the overall trend is down.
| Factor | Score |
|---|---|
| Medical Imaging Market Growth | 85 |
| AI in Healthcare | 80 |
| Disruptive Technology | 70 |
| Regulatory Approval & Adoption Hurdles | 50 |
| Competition | 65 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 5 |
| Growth | 40 |
| Balance Sheet Health | 90 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Performance | 10 |
| Volume Confirmation | 50 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Market Capitalization and Float
The company has a market capitalization of $328,177,472 with a shares float of 61,043,036, indicating a mid-cap company with a substantial portion of its shares available for trading.
Cash Position and Debt
As of Q4 2024, the company holds $39,304,000 in cash equivalents and has a debt level of $7,446,000. The company's cash position is more than 5 times its total debt, suggesting a strong ability to manage its liabilities and fund operations.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with TTM net income at -$40.939M and negative EPS (-$0.91). This indicates ongoing profitability challenges.
Negative Gross and Operating Margins
Gross Profit is negative (-$10.609M in 2024) and Operating Income is also negative (-$56.746M in 2024), indicating that the core business operations are not yet profitable and are incurring losses.
Calendar
August 2025
20
Next Earnings Date
H: $-0.14
A: $-0.15
L: $-0.16
H: 3.40M
A: 3.20M
L: 3.08M
Profile
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. It provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source; and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide and obtain remote interpretations of imaging data; Nanox.CONNECT to receive local regulatory approvals and explore and evaluate the business model and the potential service; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers and mobile imaging service providers, urgent care facilities, and multi-specialty physician groups. The company was founded in 2011 and is headquartered in Petah Tikva, Israel.
Seasonals
Price Target
8.75 USD
The 39 analysts offering 1 year price forecasts for NNOX have a max estimate of 10.00 and a min estimate of 7.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major incumbent in diagnostic imaging (X-ray, CT, MRI, Ultrasound). Direct competitor and market NNOX aims to disrupt/complement, representing traditional imaging solutions.
Weight: 95
Global leader in medical imaging, diagnostics, and therapy. Direct competitor to NNOX's ambitions, offering comprehensive imaging portfolios.
Weight: 90
Strong presence in diagnostic imaging systems, image-guided therapy, and connected care. A key competitor in the broader medical imaging market.
Weight: 88
Leading independent supplier of X-ray tubes and digital detectors, core components of traditional X-ray systems, which NNOX's digital source aims to replace.